Data from routine outpatient consultations at weeks 0, 1, 6, and 12 were compared with those obtained by 2 teledermatologists (TD1 and TD2) with particular attention to the accuracy of PASI/PPPASI scores and therapeutic outcome assessments (Ն50% reduction from baseline PASI/PPPASI scores [PASI/PPPASI 50] at week 12). 4 Based on the face-to-face assessments (FTF), PASI/ PPPASI 50 responders were continued on etanercept treatment regimens.
Results. All eligible patients (6 men and 4 women; median age, 40 years; age range, 25-67 years) agreed to participate in the study. Eight patients had plaque psoriasis, and 2 presented with palmoplantar psoriasis. Each of the 10 patients transmitted 8 "mobile visits" (total, 80 visits) including 32 to 64 images each (total, 486). Image quality was very good for an average of 86% of the images (range, 66%-95%); satisfactory for 12% (range, 5%-28%); and poor for 2% (range, 0%-6%).
The PASI/PPPASI scores correlated significantly between the FTF and the 2 teledermatologists (r = 0.71-0.96 for TD1 and r=0.78-0.98 for TD2) (Table) as well as between the 2 teledermatologists (r=0.93) (PϽ.001). The interrater variability (mean PASI/PPPASI deviation from FTF) was very low for both teledermatologists, with values ranging from 0.86 to 3.39. For patient outcomes, TD1 agreed 8 of 10 times with FTF (=0.52), and TD2 agreed with FTF 9 of 10 times (=0.78). Therapeutic outcome marginally differed in 2 patients. In one case, FTF assessed a PASI/PPPASI 50, while the teledermatologists found a 44% (TD1) and 24% (TD2) PASI/ PPPASI improvement from baseline to week 12. In the other case, TD1 calculated a PASI/PPPASI 50, while TD2 found a 47% and FTF a 44% PASI/PPPASI improvement. Palmoplantar psoriasis ratings were completely concordant.
Comment.
For the first time, to our knowledge, we have assessed the feasibility of a patient-driven mobile homemonitoring system for high-need patients with psoriasis, which actively integrates them into their treatment process. We have demonstrated a strong correlation between severity measurements obtained by an FTF physician and teledermatologists (Table) and a good con- cordance of PASI/PPPASI 50 assessments and management decisions. Because severity scorings differed mainly in diverse estimations of the involved area and induration of the lesions, one may speculate that the divergence might have resulted from the inability of the teledermatologists to see the entire body and to palpate the lesions, or it might have resulted from some flaws of the PASI scoring system for which an interrater variability of up to 8.1 PASI scores has been described. 5 In our study, the interrater variability was very low (Table) , indicating that mobile teledermatology is a feasible method for monitoring disease severity in patients with psoriasis. Larger controlled studies are required to evaluate the impact of remote follow-up care on patient empowerment and its influence on the therapeutic outcome. 
